Annexon, Inc. (ANNX)

4.8800 +0.2200 (+4.72%) At close: 04:00PM EDT

Annexon, Inc.

1400 Sierra Point Parkway
Building C Suite 200
Brisbane, CA 94005
United States
650 822 5500
https://www.annexonbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 71

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Douglas Love Esq., J.D.	CEO, President & Director	980.12k	N/A	1968
Dr. Dean R. Artis Ph.D.	Chief Scientific Officer & Executive VP	797.38k	N/A	1961
Dr. Ted Yednock Ph.D.	Executive VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board	697.76k	N/A	1958
Ms. Jennifer Lew	Executive VP, CFO & Corporate Secretary	624.2k	N/A	1973
Mr. Michael Overdorf M.B.A.	Executive VP & Chief Business Officer	580.47k	N/A	1971
Henk-Andre Kroon M.D.	Senior Vice President of Translational Medicine	N/A	N/A	N/A
Dr. Jamie Dananberg M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1958

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Corporate Governance

Annexon, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.